Expert Interview
A second look: Discussing the potential of Sagimet's denifanstat in Biopsy-Confirmed F2/F3 NASH with a focus on the Phase 2b FASCINATE-2 trial
Ticker(s): SGMTInstitution: Weill Cornell Medicine
- Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Weill Cornell Medicine in New York City
- Manages 20-30 NASH patients with stage2/3 fibrosis
- Specializes in management of patients with liver diseases including autoimmune liver disease, viral hepatitis B and C,
fatty liver disease, metabolic liver disease, and liver cancers. - Sees patients with endstage liver disease and evaluates those who need liver transplantation, provide medical care to patients before and after liver transplantation
- Special interest in healthcare disparities research
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
